Literature DB >> 15711249

Pathological stage does not alter the prognosis for renal lesions determined to be stage T1 by computerized tomography.

William W Roberts1, Sam B Bhayani, Mohamad E Allaf, Theresa Y Chan, Louis R Kavoussi, Thomas W Jarrett.   

Abstract

PURPOSE: Pathological stage has been the most widely used prognosticator for evaluating surgically managed cases of renal cell carcinoma. Minimally invasive surgical approaches are being increasingly used to treat small masses for which traditionally pathological information is lacking (morcellation) or absent (radio frequency ablation or cryoablation). Preoperative cross-sectional imaging by computerized tomography (CT) or magnetic resonance imaging has been used to stage renal tumors clinically but it can lead to variances with traditional pathological staging systems, particularly with respect to microscopic invasion beyond the renal capsule. In this study we assessed whether radiographically staged clinical T1 lesions that were pathological T1 behave differently than those that were clinical stage T1 and up staged to pT3a.
MATERIALS AND METHODS: The records of 296 patients who underwent surgical treatment for renal cell carcinoma at The Johns Hopkins Hospital between 1990 and 1999 were retrospectively reviewed. All patients had undergone preoperative CT or magnetic resonance imaging, which was used to assign a clinical stage and size (largest diameter) to each tumor in accordance with the 1997 TNM staging system. Following surgical resection pathological stage, size and tumor grade were determined. Only the 186 patients with clinical T1 tumors were included in this analysis.
RESULTS: Of the 186 patients who were clinically found to have T1 lesions 125 (67%) had pathological T1 and 57 (31%) had pathological T3a lesions. All surgical margins and lymph nodes were negative at surgical resection. Mean tumor size +/- SD was 3.9 +/- 1.5 cm for pT1 lesions and 3.8 +/- 1.5 cm for pT3a lesions. When comparing these pathological groups using Kaplan-Meier analysis, 5-year recurrence-free survival was not statistically different in patients with pT1 and pT3a lesions (90.6 and 97.5%, respectively).
CONCLUSIONS: Patients in whom the initial classification of T1 renal cell carcinoma by CT was up graded to T3a on pathological analysis (invasion of fat within Gerota's fascia) showed the same recurrence-free survival rate as patients with pathologically confirmed T1 lesions. Thus, smaller tumors (less than 7 cm) that are up graded to T3a based on capsule invasion behave much like T1 tumors and exact pathological T staging does not appear to impact overall survival.

Entities:  

Mesh:

Year:  2005        PMID: 15711249     DOI: 10.1097/01.ju.0000153638.15018.58

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors.

Authors:  Pascal Mouracade; Onder Kara; Julien Dagenais; M J Maurice; R J Nelson; Ercan Malkoc; J H Kaouk
Journal:  World J Urol       Date:  2017-02-14       Impact factor: 4.226

Review 2.  Early renal cell cancer.

Authors:  Yoshihiko Tomita
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.402

3.  Prognostic Evaluation of the Site of Invasion in Pathological Stage T3a Renal Cell Carcinoma.

Authors:  Gu-Shun Lai; Jian-Ri Li; Shian-Shiang Wang; Chuan-Shu Chen; Chun-Kuang Yang; Sheng-Chun Hung; Chen-Li Cheng; Yen-Chuan Ou; Kun-Yuan Chiu
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

4.  Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.

Authors:  Paul L Crispen; Rosalia Viterbo; Stephen A Boorjian; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

5.  Prognostic significance of perirenal infiltration in renal cell carcinoma (<7 cm).

Authors:  Seongyub Oh; Jangho Yoon; Dongil Kang; Heung Lae Cho; Jae-il Chung
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

6.  Survival Analysis of Pathological T3a Upstaging in Clinical T1 Renal Cell Carcinoma.

Authors:  Gu-Shun Lai; Jian-Ri Li; Shian-Shiang Wang; Chuan-Shu Chen; Chun-Kuang Yang; Sheng-Chun Hung; Chen-Li Cheng; Yen-Chuan Ou; Kun-Yuan Chiu
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

7.  Approach to the small renal mass: weighing treatment options.

Authors:  Brian M Benway; Sam B Bhayani
Journal:  Curr Urol Rep       Date:  2009-01       Impact factor: 3.092

8.  Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004-2013.

Authors:  Amanda Ghanie; Margaret K Formica; Dongliang Wang; Gennady Bratslavsky; Telisa Stewart
Journal:  Int Urol Nephrol       Date:  2017-12-15       Impact factor: 2.370

9.  Predicting growth of solid renal masses under active surveillance.

Authors:  Paul L Crispen; Yu-Ning Wong; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Urol Oncol       Date:  2008 Sep-Oct       Impact factor: 3.498

10.  Pathological T3a Upstaging of Clinical T1 Renal Cell Carcinoma: Outcomes According to Surgical Technique and Predictors of Upstaging.

Authors:  Seung-Hwan Jeong; Jung Kwon Kim; Juhyun Park; Ho Joon Jeon; Min Young Yoon; Chang Wook Jeong; Ja Hyeon Ku; Hyeon Hoe Kim; Cheol Kwak
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.